Evercore ISI raises BioMarin stock price target on valuation gap

BioMarin reported Q1 2026 EPS of $0.76, beating the $0.74 estimate, on revenue of $766 million versus $755.94 million expected. Evercore ISI raised its price target to $120 from $110 while keeping an Outperform rating, citing a valuation disconnect and upcoming catalysts including two Phase 3 readouts in Q2 2026 and BMN 333 data next year. The stock trades at $55.46, and the company said Voxzogo-treated patients rose 20% year over year.

Analysis

BMRN’s setup is less about a clean earnings beat and more about the market re-underwriting the durability of a mid-cap rare-disease franchise. The key second-order effect is that management’s ability to preserve share despite a new acquisition-driven revenue base suggests the competitive moat is still being defended by switching friction, not just product superiority. That matters because in orphan/ultra-rare markets, pricing power can persist longer than consensus expects when prescribers face operational inertia.

The larger debate is whether the stock is being valued like a slow-growth biotech while the pipeline now looks like a multi-catalyst option on 2026-2027. Near term, the equity may stay capped because the next meaningful read-through is months away and the market will likely demand proof that Voxzogo growth can re-accelerate after incorporation of the acquired asset base. But if the next two Phase 3 data sets land positive, the stock can re-rate quickly because the current multiple appears to be discounting a materially lower probability of pipeline success than the cash balance and commercial execution warrant.

The contrarian risk is that investors are overemphasizing reported demand resilience and underestimating how quickly physician switching dynamics can normalize once competitors or payer pressure intensify. If growth decelerates even modestly over the next 1-2 quarters, the current narrative of valuation disconnect can compress back toward a cash-flow multiple rather than a pipeline multiple. That makes this a timing trade: the upside is real, but the path likely needs a catalyst bridge or the shares may remain range-bound until late-stage data visibility improves.

Key Decisions for Investors

• Initiate a tactical long in BMRN on any 3-5% post-earnings weakness; target a 3-6 month hold into the next clinical readout window with upside driven by multiple expansion rather than near-term estimate revisions.
• Buy BMRN Jan-2027 calls financed by selling nearer-dated calls against the position; this captures the 2026 catalyst stack while reducing theta if the stock remains range-bound for the next 2-3 quarters.
• Pair trade: long BMRN / short a higher-beta profitable biotech with less visible catalysts over the next 12 months; the relative value case is strongest if investors rotate toward cash-rich names ahead of binary data events.
• If BMRN rallies >15% on sentiment alone before clinical data, trim one-third to one-half of the position; the near-term upside is likely to be pulled forward from the 2026 catalyst set, creating a crowded entry point.
• For more aggressive portfolios, structure a call spread into the next Phase 3 window rather than outright stock; risk/reward is asymmetric because downside is limited by balance-sheet strength, but upside requires a positive data surprise.